

Erbitux[®] (cetuksymab)



Analiza kliniczna

Wersja 1.1

Warszawa – Kraków 2014

Wykonawcy:**Aestimo s.c.** [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Internet: <http://www.aestimo.eu>E-mail: biuro@aestimo.eu**Health Economics Consulting**

[REDACTED]

[REDACTED]

[REDACTED]

Internet: www.hec.plE-mail: rafal.zysk@hec.pl**Autorzy:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Koordinacja merytoryczna projektu:

[REDACTED]






* - autor do korespondencji: Marcin Kaczor; 31-062 Kraków, ul. Krakowska 36/3; marcin.kaczor@aestimo.eu

Konflikt interesów:

Raport został wykonany na zlecenie i sfinansowany przez firmę Merck Sp. z o.o.

Autorzy nie zgłosili konfliktu interesów.

Spis treści

1. Analiza kliniczna	3
	
	
	
	
	
1.2. Piśmiennictwo	11

Analiza kliniczna

Rozdział

I

Skuteczność oraz bezpieczeństwo stosowania cetuksymabu

[Redacted text block]

[Redacted text block]

[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]

[Redacted text block]

		Warianty leczenia			Warianty leczenia		
		W1	W2	W3	W1	W2	W3
I	1	1	1	1	1	1	1
	2	1	1	1	1	1	1
II	1	1	1	1	1	1	1
	2	1	1	1	1	1	1
III	1	1	1	1	1	1	1
	2	1	1	1	1	1	1
	3	1	1	1	1	1	1
IV	1	1	1	1	1	1	1
	2	1	1	1	1	1	1

[Redacted text block]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]		
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]


[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



[Redacted text block containing multiple lines of blacked-out text]

[Redacted text block]